Cancer is one of the most mortality diseases in the world, and humans need to find new cancer drugs. Using various chromatographic techniques, we isolated and purified a cyclic pentapeptide compound Galaxamide from marine algae Collected in Yongxing Island, Xisha Islands, China. Galaxamide Total synthesis and structural modification was performed. Galaxamide Against the proliferation of cervical cancer cells Hela and human breast cancer cells MDA-MB-231. Through mouse Hela cervical cancer and MDA-MB-231 breast cancer graft model study, Galaxamide inhibited tumor growth and its tumor suppression rate was 61% and 68%, respectively. Galaxamide The exposure level in SD rats was 329.26h · ng/mL, the half-life T1 / 2 was 3.21h, clearance 3026.40mL/h/kg, and apparent volume of distribution 13952.75mL/kg. Galaxamide Has less toxicity in vivo. It is worth further study on Galaxamide and is expected to become a new generation of anti-tumor Marine drugs.

Xu Shihai graduated from Sun Yat-sen University in July 1996. Since July 1996, he has been engaged in anti-tumor Marine drug research in Jinan University. He is a professor and doctoral supervisor of Jinan University in China. He is also the vice chairman of China Marine Pharmaceutical Professional Committee. He has undertaken 3 research projects of China Ocean 863 Program, 7 National Natural Science Foundation of China and 3 research projects of Guangdong Marine and Fishery Bureau of China. He has published 150 research papers and been approved 16 Chinese invention patents.